124 related articles for article (PubMed ID: 10743925)
1. Threshold power levels for NPe6 photodynamic therapy.
Kazi AA; Peyman GA; Unal M; Khoobehi B; Yoneya S; Mori K; Moshfeghi D; Moshfeghi AA
Ophthalmic Surg Lasers; 2000; 31(2):136-42. PubMed ID: 10743925
[TBL] [Abstract][Full Text] [Related]
2. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6).
Mori K; Yoneya S; Ohta M; Sano A; Anzai K; Peyman GA; Moshfeghi DM
Ophthalmology; 1999 Jul; 106(7):1384-91. PubMed ID: 10406627
[TBL] [Abstract][Full Text] [Related]
3. Threshold and retreatment parameters of NPe6 photodynamic therapy in retinal and choroidal vessels.
Peyman GA; Kazi AA; Moshfeghi D; Unal M; Khoobehi B; Yoneya S; Mori K; Rivera I
Ophthalmic Surg Lasers; 2000; 31(4):323-7. PubMed ID: 10928670
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the new photosensitizer Tookad (WST09) for photodynamic vessel occlusion of the choroidal tissue in rabbits.
Framme C; Sachs HG; Flucke B; Theisen-Kunde D; Birngruber R
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5437-46. PubMed ID: 17122134
[TBL] [Abstract][Full Text] [Related]
5. PDT to monkey CNV with ATX-S10(Na): inappropriateness of early laser irradiation for selective occlusion.
Obana A; Gohto Y; Kaneda K; Nakajima S; Miki T
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2639-45. PubMed ID: 11581211
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6.
Mori K; Yoneya S; Anzail K; Kabasawa S; Sodeyama T; Peyman GA; Moshfeghi DM
Retina; 2001; 21(5):499-508. PubMed ID: 11642380
[TBL] [Abstract][Full Text] [Related]
7. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies.
Moshfeghi DM; Peyman GA; Moshfeghi AA; Khoobehi B; Primbs GB; Crean DH
Ophthalmic Surg Lasers; 1998 Aug; 29(8):663-8. PubMed ID: 9715492
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2).
Peyman GA; Moshfeghi DM; Moshfeghi A; Khoobehi B; Doiron DR; Primbs GB; Crean DH
Ophthalmic Surg Lasers; 1997 May; 28(5):409-17. PubMed ID: 9150524
[TBL] [Abstract][Full Text] [Related]
9. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
Mori K; Ohta M; Sano A; Yoneya S; Sonoda M; Kaneda A; Sato Y
Nippon Ganka Gakkai Zasshi; 1997 Feb; 101(2):134-40. PubMed ID: 9124093
[TBL] [Abstract][Full Text] [Related]
10. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence properties of a hydrophilic sensitizer in pigmented rats, rabbits, and monkeys.
Moshfeghi D; Peyman GA; Kazi AA; Unal M; Khoobehi B; Yoneya S; Mori K
Ophthalmic Surg Lasers; 1999; 30(9):750-3. PubMed ID: 10574497
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes.
Berdugo M; Bejjani RA; Valamanesh F; Savoldelli M; Jeanny JC; Blanc D; Ficheux H; Scherz A; Salomon Y; BenEzra D; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1633-44. PubMed ID: 18385085
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
14. Problems with and pitfalls of photodynamic therapy.
Peyman GA; Kazi AA; Unal M; Khoobehi B; Yoneya S; Mori K; Moshfeghi DM
Ophthalmology; 2000 Jan; 107(1):29-35. PubMed ID: 10647715
[TBL] [Abstract][Full Text] [Related]
15. Scanning laser system for photodynamic therapy of choroidal neovascularization.
Obana A; Gohto Y
Lasers Surg Med; 2002; 30(5):370-5. PubMed ID: 12116330
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of experimentally induced choroidal neovascularizations in pigmented rabbits by subretinal injection of lipid hydroperoxide and consecutive preliminary photodynamic treatment with Tookad.
Framme C; Sachs HG; Kobuch K; Flucke B; Birngruber R
Ophthalmologica; 2008; 222(4):254-64. PubMed ID: 18525218
[TBL] [Abstract][Full Text] [Related]
17. Experimental photodynamic effects of hypocrellin A on the choriocapillaris.
Khoobehi B; Grinstead R; Passos E
Ophthalmic Surg Lasers; 2002; 33(3):207-13. PubMed ID: 12027100
[TBL] [Abstract][Full Text] [Related]
18. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
19. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
20. Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys.
Obana A; Gohto Y; Kanai M; Nakajima S; Kaneda K; Miki T
Arch Ophthalmol; 2000 May; 118(5):650-8. PubMed ID: 10815157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
